Doxycycline hyclate CR is a small molecule commercialized by PolyPid, with a leading Phase III program in Surgical Wound Infections. According to Globaldata, it is involved in 6 clinical trials, of which 4 were completed, 1 is ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Doxycycline hyclate CR’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Doxycycline hyclate CR is expected to reach an annual total of $52 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Doxycycline hyclate CR Overview
Doxycycline hyclate is under development for the prevention of post cardiac surgery sternal infections and post abdominal surgery incisional infections. It is administered by topical route. It is a controlled formulation impregnated into a synthetic beta tri-calcium phosphate. The drug candidate is based on PLEX (polymer lipid encapsulation matrix) technology.
See Also:
PolyPid Overview
PolyPid is pharmaceutical company that develops, manufactures and markets therapies for the treatment of infection, cancer, inflammation and pain. The company product comprise D-Plex100 for the potential approval for prevention of abdominal (soft) tissue SSIs and OncoPlex for intra-tumoral cancer therapy. The company’s PLEX, a drug delivery technology that enables the determination of rates and durations to optimize the treatment regimens. Its PLEX (Polymer-Lipid Encapsulation matriX) platform is a matrix made of alternating layers of polymers and lipids that entrap a therapeutic drug. The company operates in the USA and Israel. PolyPid is headquartered in Petah Tikva, Israel.
The operating loss of the company was US$38.9 million in FY2022, compared to an operating loss of US$43.2 million in FY2021. The net loss of the company was US$39.6 million in FY2022, compared to a net loss of US$42.6 million in FY2021.
For a complete picture of Doxycycline hyclate CR’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
